Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioray Biotech CoROCO:7561 -9.19%86 EV-to-EBIT is 18.25 as of Sep. 21, 2026, which is 123% above its 10-year median of 8.20. GuruFocus rates ROCO:7561 with a GF Score™ of 86/100 and a GF Value™ of NT$24.39 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 682 Drug Manufacturers companies, Bioray Biotech Co ranks worse than 54.55% on this metric.
Bioray Biotech Co (ROCO:7561) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bioray Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$495.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$25.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co EV-to-EBIT Related Terms
Bioray Biotech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's EV-to-EBIT falls into.
Bioray Biotech Co's current Enterprise Value is NT$460.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$25.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co (ROCO:7561) has a EV-to-EBIT of 18.25 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioray Biotech Co and its competitors. This is 123% above median its historical median of 8.20. According to the industry distribution chart, Bioray Biotech Co ranks #372 out of 682 companies in the Drug Manufacturers industry, placing it in the top 54.5%.
Is Bioray Biotech Co's EV-to-EBIT too high?
Bioray Biotech Co's current EV-to-EBIT of 18.25 is 123% above median its 10-year median of 8.20. The Drug Manufacturers industry median EV-to-EBIT is 16.08. Bioray Biotech Co's value of 18.25 is 13.5% above this industry median. Based on the distribution chart, Bioray Biotech Co ranks #372 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bioray Biotech Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #372 out of 682 companies for EV-to-EBIT. This places Bioray Biotech Co in the lower half of its industry. The industry median EV-to-EBIT is 16.08. Bioray Biotech Co's value of 18.25 is 13.5% above this benchmark. While the company's 10-year median is 8.20 vs. the industry median of 16.08, Bioray Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current EV-to-EBIT of 18.25 is 13.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current EV-to-EBIT is 18.25, which is 123% above median its own 10-year median of 8.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$24.39, compared to a current price of NT$20.25 — trading 17% below its estimated fair value. The current EV-to-EBIT is 18.25, which is 123% above median its 10-year median of 8.20 and 13.5% above the Drug Manufacturers industry median of 16.08. Bioray Biotech Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current EV-to-EBIT is 18.25 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$20.25 is trading 17% below its estimated GF Value™ of NT$24.39.
GuruFocus considers Bioray Biotech Co to be Modestly Undervalued.
Key valuation signals for ROCO:7561:
EV-to-EBIT: 18.25 (123% above median its 10-year median of 8.20)
GF Value™: NT$24.39 vs. price of NT$20.25 (17% below fair value)
Industry Position: 13.5% above the Drug Manufacturers median (#372 of 682)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
86GF Score
Get the complete analysis for ROCO:7561
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
